Lu AE58054 Lundbeck Starbright Study
To establish efficacy of Lu AE58054 as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
NOBLE - TCAD Study
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories, physical examinations, ECGs and solicitation of adverse events. To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric Inventory (NPI) and Mini-mental State Examination (MMSE).
A4: Drug study for individuals with a strong family history of Alzheimer’s that asymptomatic
Statuts: Not Open for Enrollment Yet
A16: Autopsy study for Alzheimer’s
Status: Not Open for Enrollment Yet
For more information
Clinical Research Coordinator:
Jennifer Garrett, RN